Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (propiolactone inactivated) (unii: 0qk4u2v88l) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:re1mnp1ne6), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (propiolactone inactivated) (unii: al8g7d406d) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:mu3in5k1yc), influenza b virus b/maryland/15/2016 antigen (propiolacto - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated ba

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) antigen (propiolactone inactivated) (unii: ytl6a60f5i) (influenza a virus a/victoria/2454/2019 ivr-207 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:540gm6ll7u), influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) antigen (propiolactone inactivated) (unii: oat4h11zt6) (influenza a virus a/hong kong/2671/2019 ivr-208 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:pc99fhq5w6), influenza b virus b/victoria/705/2018 bv - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated ba

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (propiolactone inactivated) (unii: 6f59dl4eet) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:qwb7m7p3k9), influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) antigen (propiolactone inactivated) (unii: y9cjf75rbv) (influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:lw2jc76p6m), influenza b virus b/victoria/705/2 - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11] ) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (propiolactone inactivated) (unii: uph9lrj9hu) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:x5dyv3mm4n), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (propiolactone inactivated) (unii: n4uxa9h8ka) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:zn6bmn7fsq), influenza b virus b/austria/1359417/2021 bvr-26 anti - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated b

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - salmonella typhi -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - salmonella typhi, quantity: 2000 million organisms - capsule, enteric - excipient ingredients: sucrose; ascorbic acid; protein hydrolysate; ethylene glycol; lactose; hypromellose phthalate; erythrosine; iron oxide red; titanium dioxide; magnesium stearate; diethyl phthalate; gelatin; iron oxide yellow - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 7.5 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.